NYSE:BDXMedical Equipment
Is Becton Dickinson (BDX) Undervalued As Its Brazil Semaglutide Partnership Fuels Growth Hopes?
Becton Dickinson (BDX) is back in focus after announcing a collaboration with EMS to launch a semaglutide therapy in Brazil, using BD’s Vystra injection pen platform for chronic disease treatment.
See our latest analysis for Becton Dickinson.
Becton Dickinson’s recent collaboration news comes on the heels of a 10.92% 90 day share price return, even as the year to date share price return is down 15.04%. The 1 year total shareholder return of 22.43% points to momentum rebuilding after weaker...